Patents by Inventor Huafei ZOU

Huafei ZOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 11865160
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 9, 2024
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • FUSION PROTEIN OF SINGLE DOMAIN ANTIBODY AND PROCOAGULANT
    Publication number: 20220041716
    Abstract: The present invention relates to single domain antibodies (sdAbs) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1) molecules that are present on activated platelets at the site of an injury, and especially on a subset of activated platelets, coated platelets. Furthermore, the present invention relates to fusion proteins comprising sdAbs against TLT-1 and an extracellular (soluble) domain of tissue factor (sTF), to direct targeting of such fusion proteins to activated platelets at the site of injury through binding of the sdAbs to TLT-1, a membrane protein receptor that is only present on activated platelets. Specific interaction of sdAbs with the TLT-1 receptor positions the sTF domain of the fusion to interact with, and activate, FVII. As a result, a targeted procoagulant effect is achieved at the site of injury via activated platelets.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Qi LI, Huafei ZOU
  • MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
    Publication number: 20220000981
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: May 11, 2021
    Publication date: January 6, 2022
    Inventors: Weijun SHEN, Pengyu YANG, Huafei ZOU, Peter G. SCHULTZ
  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 11007252
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 18, 2021
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
    Publication number: 20180344812
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: June 5, 2018
    Publication date: December 6, 2018
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 10039809
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 7, 2018
    Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 10010589
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: July 3, 2018
    Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Oxyntomodulin analogs and methods of making and using same
    Patent number: 9931379
    Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: April 3, 2018
    Assignees: The Research Foundation for The State University of New York, California Institute for Biomedical Research
    Inventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
  • OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME
    Publication number: 20170196940
    Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 13, 2017
    Inventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
  • MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
    Publication number: 20160317623
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Inventors: Weijun SHEN, Pengyu YANG, Huafei ZOU, Peter G. SCHULTZ